OBJECTIVE: To determine whether peripheral blood mononuclear cells (PBMCs) from children with recent-onset polyarticular juvenile idiopathic arthritis (JIA) exhibit biologically or clinically informative gene expression signatures. METHODS: Peripheral blood samples were obtained from 59 healthy children and 61 children with polyarticular JIA prior to treatment with second-line medications, such as methotrexate or biologic agents. RNA was extracted from isolated mononuclear cells, fluorescence labeled, and hybridized to commercial gene expression microarrays (Affymetrix HG-U133 Plus 2.0). Data were analyzed using analysis of variance at a 5% false discovery rate threshold after robust multichip analysis preprocessing and distance-weighted discrimination normalization. RESULTS: Initial analysis revealed 873 probe sets for genes that were differentially expressed between polyarticular JIA patients and healthy controls. Hierarchical clustering of these probe sets distinguished 3 subgroups within the polyarticular JIA group. Prototypical patients within each subgroup were identified and used to define subgroup-specific gene expression signatures. One of these signatures was associated with monocyte markers, another with transforming growth factor beta-inducible genes, and a third with immediate early genes. Correlation of gene expression signatures with clinical and biologic features of JIA subgroups suggested relevance to aspects of disease activity and supported the division of polyarticular JIA into distinct subsets. CONCLUSION: Gene expression signatures in PBMCs from patients with recent-onset polyarticular JIA reflect discrete disease processes and offer a molecular classification of disease.
OBJECTIVE: To determine whether peripheral blood mononuclear cells (PBMCs) from children with recent-onset polyarticular juvenile idiopathic arthritis (JIA) exhibit biologically or clinically informative gene expression signatures. METHODS: Peripheral blood samples were obtained from 59 healthy children and 61 children with polyarticular JIA prior to treatment with second-line medications, such as methotrexate or biologic agents. RNA was extracted from isolated mononuclear cells, fluorescence labeled, and hybridized to commercial gene expression microarrays (Affymetrix HG-U133 Plus 2.0). Data were analyzed using analysis of variance at a 5% false discovery rate threshold after robust multichip analysis preprocessing and distance-weighted discrimination normalization. RESULTS: Initial analysis revealed 873 probe sets for genes that were differentially expressed between polyarticular JIA patients and healthy controls. Hierarchical clustering of these probe sets distinguished 3 subgroups within the polyarticular JIA group. Prototypical patients within each subgroup were identified and used to define subgroup-specific gene expression signatures. One of these signatures was associated with monocyte markers, another with transforming growth factor beta-inducible genes, and a third with immediate early genes. Correlation of gene expression signatures with clinical and biologic features of JIA subgroups suggested relevance to aspects of disease activity and supported the division of polyarticular JIA into distinct subsets. CONCLUSION: Gene expression signatures in PBMCs from patients with recent-onset polyarticular JIA reflect discrete disease processes and offer a molecular classification of disease.
Authors: R E Petty; T R Southwood; J Baum; E Bhettay; D N Glass; P Manners; J Maldonado-Cocco; M Suarez-Almazor; J Orozco-Alcala; A M Prieur Journal: J Rheumatol Date: 1998-10 Impact factor: 4.666
Authors: M Gattorno; P Facchetti; F Ghiotto; S Vignola; A Buoncompagni; I Prigione; P Picco; V Pistoia Journal: Clin Exp Immunol Date: 1997-07 Impact factor: 4.330
Authors: S Wijngaarden; J A G van Roon; J G J van de Winkel; J W J Bijlsma; F P J G Lafeber Journal: Rheumatology (Oxford) Date: 2005-03-09 Impact factor: 7.580
Authors: Lone Frier Bovin; Klaus Rieneck; Christopher Workman; Henrik Nielsen; Søren Freiesleben Sørensen; Henrik Skjødt; Adrian Florescu; Søren Brunak; Klaus Bendtzen Journal: Immunol Lett Date: 2004-05-15 Impact factor: 3.685
Authors: A Bucht; P Larsson; L Weisbrot; C Thorne; P Pisa; G Smedegård; E C Keystone; A Grönberg Journal: Clin Exp Immunol Date: 1996-03 Impact factor: 4.330
Authors: Rae S M Yeung; Salvatore Albani; Brian M Feldman; Elizabeth Mellins; Berent Prakken; Lucy R Wedderburn Journal: Nat Rev Rheumatol Date: 2016-09-22 Impact factor: 20.543
Authors: Michael G Barnes; Alexei A Grom; Thomas A Griffin; Robert A Colbert; Susan D Thompson Journal: Biopreserv Biobank Date: 2010-09-29 Impact factor: 2.300
Authors: Halima Moncrieffe; Mark F Bennett; Monica Tsoras; Lorie K Luyrink; Anne L Johnson; Huan Xu; Jason Dare; Mara L Becker; Sampath Prahalad; Margalit Rosenkranz; Kathleen M O'Neil; Peter A Nigrovic; Thomas A Griffin; Daniel J Lovell; Alexei A Grom; Mario Medvedovic; Susan D Thompson Journal: Rheumatology (Oxford) Date: 2017-09-01 Impact factor: 7.580
Authors: Jill A Hollenbach; Susan D Thompson; Teodorica L Bugawan; Mary Ryan; Marc Sudman; Miranda Marion; Carl D Langefeld; Glenys Thomson; Henry A Erlich; David N Glass Journal: Arthritis Rheum Date: 2010-06
Authors: Allison A Throm; Halima Moncrieffe; Amir B Orandi; Jeanette T Pingel; Theresa L Geurs; Hannah L Miller; Allyssa L Daugherty; Olga N Malkova; Daniel J Lovell; Susan D Thompson; Alexei A Grom; Megan A Cooper; Stephen T Oh; Anthony R French Journal: JCI Insight Date: 2018-08-09